Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Abramson Cancer Center at Penn Medicine
Bayer
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Institut Curie
Mayo Clinic
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Genentech, Inc.
Duke University
Novartis
National Institutes of Health Clinical Center (CC)
Region Skane
Tvardi Therapeutics, Incorporated
Labcorp Corporation of America Holdings, Inc
Stanford University
BioAtla, Inc.
Universitair Ziekenhuis Brussel
Eli Lilly and Company
AstraZeneca
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institut Cancerologie de l'Ouest
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
University of Southern California
Cedars-Sinai Medical Center
Exelixis
Eli Lilly and Company
Celldex Therapeutics
NextCure, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
Xencor, Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Prelude Therapeutics
Nektar Therapeutics
Herlev Hospital
Quadriga Biosciences, Inc.
Milton S. Hershey Medical Center
Institut de Cancérologie de Lorraine
Ludwig Institute for Cancer Research
Xencor, Inc.
Scripps Health
Ludwig Institute for Cancer Research
Incyte Corporation